Fig. 1 · Structure

Documents & Downloads

Nicorandil

Cat. No. A10641 CAS 65141-46-0

Kir6 (KATP) channel opener

Nicorandil (SG-75) is potassium channel activator.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Potassium channel

Nicorandil Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Nicorandil from 3 published references. In vitro models include serum-starved HUVECs; HL-1 cells.

Nicorandil In Vitro Studies

In serum-starved HUVECs, Nicorandil at 100 µmol/L induced time-dependent Akt serine-473 phosphorylation, reaching a maximum 3.0-fold increase. In HL-1 cells, preincubation with Nicorandil at 30 μM, 50 μM or 100 μM for 90 min before L-arginine addition activated the NO accumulation rate. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Time-Dependent Akt Phosphorylation in Serum-Starved HUVECs

Cell-based study · serum-starved HUVECs [1]

Serum-starved HUVECs were stimulated with Nicorandil at 100 µmol/L. Nicorandil induced time-dependent Akt serine-473 phosphorylation, with a maximum 3.0-fold increase.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Akt serine-473 phosphorylationAkt serine-473 phosphorylation maximum 3.0-fold increase[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 µmol/L
Exposure duration
for the indicated time intervals
Method
stimulated
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Nicorandil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell culture (S32); Results > Nicorandil activates the PI3K/Akt and ERK pathways in vascular endothelial cells (S83, S84); Figure 8 legend (S149)

Akt serine-473 phosphorylation: Akt serine-473 phosphorylation; comparator: control (no drug) — Results > Nicorandil activates the PI3K/Akt and ERK pathways in vascular endothelial cells (S84)

Nitric Oxide Accumulation After Preincubation in Cardiac Cells

Cell-based study · HL-1 cells [2]

HL-1 cells were preincubated with Nicorandil at 30 μM, 50 μM or 100 μM for 90 min before L-arginine addition. This treatment activated the NO accumulation rate.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NO production rateReported result Preincubated for 90 min; 30, 50 or 100 μM nicorandil: the NO accumulation rate was activated when nicorandil was added in preincubation before the addition of L-arginine.[2]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM, 50 μM or 100 μM
Exposure duration
preincubated for 90 min
Method
added in preincubation before the addition of L-arginine
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Nicorandil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > NO production (S27); Results > NO and nicorandil (S93, S94, S95); Fig 3 legend (S160, S161)

NO production rate: NO production rate; comparator: the rate measured in the absence of nicorandil (100%) — Results > NO and nicorandil (S94, S95); Fig 3 legend (S160, S161)

Nicorandil In Vivo Studies

In studies of female mice with cardiac-specific HSPB5 R120G overexpression, oral Nicorandil was administered at 15 mg/kg/day for 4 weeks, starting at 12 weeks of age. Systolic blood pressure and heart rates did not differ among NTG mice or R120G TG mice with or without Nicorandil treatment. The increased heart weight/body weight ratio in the transgenic mice was unchanged by Nicorandil. [3]

Blood Pressure and Heart Rate in Transgenic Mice

Animal study · Female mice with cardiac-specific overexpression of mutant HSPB5 containing the R120G mutation; C57BL/6 SLC background [3]

Female mice with cardiac-specific overexpression of HSPB5 R120G received oral Nicorandil at 15 mg/kg/day for 4 weeks, starting at 12 weeks of age. No differences in systolic blood pressure or heart rates were observed among NTG mice or R120G TG mice with or without treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Systolic blood pressure (mmHg)Systolic blood pressure HSPB5 R120G TG+Nico; 15 mg/kg/day; from 12 weeks of age, for 4 weeks: 99±3 mmHg[3]

Conditions shared by the study groups

Route
oral administration
Treatment course
from 12 weeks of age; for 4 weeks
Vehicle
tap water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nicorandil 15 mg/kg/day (81 mg/l of drinking water)HSPB5 R120G TGNo differences in systolic blood pressure or heart rates were seen among NTG mice or R120G TG mice with or without nicorandil treatment[3]
Nicorandil 15 mg/kg/day (81 mg/l of drinking water)
Model: Female mice with cardiac-specific overexpression of mutant HSPB5 containing the R120G mutation; C57BL/6 SLC background
Methods and source locations

Compound reported in the paper: Nicorandil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Transgenic mice (S29, S31); Materials and Methods > Experimental design and drug treatment (S41); Results > Effect of nicorandil in R120G TG mice at a relatively early stage (S93, S95); Table 1 (T1.h1, T1.r1)

Systolic blood pressure (mmHg): Systolic blood pressure (mmHg); comparator: HSPB5 R120G TG — Materials and Methods > Experimental design and drug treatment (S41); Results > Effect of nicorandil in R120G TG mice at a relatively early stage (S93, S95); Table 1 (T1.h1, T1.r1)

Nicorandil 15 mg/kg/day (81 mg/l of drinking water) · Materials and Methods > Experimental design and drug treatment (S41); Results > Effect of nicorandil in R120G TG mice at a relatively early stage (S93, S95)

Heart Weight Relative to Body Weight in Transgenic Mice

Animal study · Female mice with cardiac-specific overexpression of mutant HSPB5 containing the R120G mutation; C57BL/6 SLC background [3]

Female mice with cardiac-specific overexpression of HSPB5 R120G received oral Nicorandil at 15 mg/kg/day for 4 weeks, starting at 12 weeks of age. The increased heart weight/body weight ratio was unchanged by treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Heart weight/body weight ratio (mg/g)Heart weight/body weight ratio HSPB5 R120G TG+Nico; 15 mg/kg/day; from 12 weeks of age, for 4 weeks: 5.7±0.1 mg/g[3]

Conditions shared by the study groups

Route
oral administration
Treatment course
from 12 weeks of age; for 4 weeks
Vehicle
tap water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nicorandil 15 mg/kg/day (81 mg/l of drinking water)HSPB5 R120G TGThis increased weight ratio was unchanged by nicorandil treatment[3]
Nicorandil 15 mg/kg/day (81 mg/l of drinking water)
Model: Female mice with cardiac-specific overexpression of mutant HSPB5 containing the R120G mutation; C57BL/6 SLC background
Methods and source locations

Compound reported in the paper: Nicorandil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Transgenic mice (S29, S31); Materials and Methods > Experimental design and drug treatment (S41); Results > Effect of nicorandil in R120G TG mice at a relatively early stage (S93, S103); Table 1 (T1.h1, T1.r4)

Heart weight/body weight ratio (mg/g): Heart weight/body weight ratio (mg/g); comparator: HSPB5 R120G TG — Materials and Methods > Experimental design and drug treatment (S41); Results > Effect of nicorandil in R120G TG mice at a relatively early stage (S93, S103); Table 1 (T1.h1, T1.r4)

Nicorandil 15 mg/kg/day (81 mg/l of drinking water) · Materials and Methods > Experimental design and drug treatment (S41); Results > Effect of nicorandil in R120G TG mice at a relatively early stage (S93, S103)

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 65141-46-0
Applications Kir6 (KATP) channel opener
Formula C8H9N3O4
Molecular Weight 211.18
SMILES
C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 39 mg/mL (184.68 mM)
Water 16 mg/mL (75.76 mM)
Ethanol 39 mg/mL (184.68 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Nicorandil Research References

  1. [1] Sahara M, Sata M, Morita T, et al. Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension. PLoS One (2012). PMID: 22479390 DOI: 10.1371/journal.pone.0033367 Source material
  2. [2] Asensio-López MC, Soler F, Pascual-Figal D, et al. Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS One (2017). PMID: 28245258 DOI: 10.1371/journal.pone.0172803 Source material
  3. [3] Sanbe A, Marunouchi T, Yamauchi J, et al. Cardioprotective effect of nicorandil, a mitochondrial ATP-sensitive potassium channel opener, prolongs survival in HSPB5 R120G transgenic mice. PLoS One (2011). PMID: 21541347 DOI: 10.1371/journal.pone.0018922 Source material

Added to your cart

View Cart Checkout
Loading...